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ackground & Aims: Idiosyncratic drug-induced liver
njury (DILI) is among the most common causes of
Drug-induced liver injury (DILI) is a serious healthproblem that impacts patients, physicians, the
pharmaceutical industry, and government regulators.1–3
DILI is the most common cause of death from acute liver
failure and accounts for approximately 13% of cases ofcute liver failure in the United States, accounting for
pproximately 13% of cases. A prospective study was
acute liver failure in the United States.4 DILI is the most
























egun in 2003 to recruit patients with suspected DILI
nd create a repository of biological samples for anal-
sis. This report summarizes the causes, clinical fea-
ures, and outcomes from the first 300 patients en-
olled. Methods: Patients with suspected DILI were
nrolled based on predefined criteria and followed up
or at least 6 months. Patients with acetaminophen
iver injury were excluded. Results: DILI was caused
y a single prescription medication in 73% of the
ases, by dietary supplements in 9%, and by multiple
gents in 18%. More than 100 different agents were
ssociated with DILI; antimicrobials (45.5%) and cen-
ral nervous system agents (15%) were the most com-
on. Causality was considered to be definite in 32%,
ighly likely in 41%, probable in 14%, possible in 10%,
nd unlikely in 3%. Acute hepatitis C virus (HCV)
nfection was the final diagnosis in 4 of 9 unlikely
ases. Six months after enrollment, 14% of patients
ad persistent laboratory abnormalities and 8% had
ied; the cause of death was liver related in 44%.
onclusions: DILI is caused by a wide array of med-
cations, herbal supplements, and dietary supple-
ents. Antibiotics are the single largest class of
gents that cause DILI. Acute HCV infection should
e excluded in patients with suspected DILI by HCV
NA testing. The overall 6-month mortality was 8%,
ut the majority of deaths were not liver related.f otherwise promising new drug candidates during
reclinical or clinical development, failure of drugs to
chieve approval by the regulatory agencies, and with-
rawal or restriction of prescription drug use after
nitial approval.1–3
Idiosyncratic DILI from any single medication is a rare
linical event occurring in less than 1 per 10,000 to
00,000 of subjects who take the drug. The risk factors
or this rare occurrence and the pathogenesis are poorly
nderstood.1–3,5,6 Most cases of DILI are unpredictable
nd generally believed to be due to an immunoallergic
eaction or an abnormality in the metabolism of the
gent and lack a dose relationship, although a dose
hreshold has been suggested recently.5,7,8 The clinical
resentation of DILI covers a wide spectrum, from
symptomatic liver test abnormalities to symptomatic
cute liver disease, prolonged jaundice and disability, or
vert acute or subacute liver failure. The recognition and
iagnosis of DILI are often difficult and delayed due to
he need to exclude more common competing causes of
iver injury.
Abbreviations used in this paper: DILI, drug-induced liver injury;
ILIN, Drug-Induced Liver Injury Network; INR, international normal-
zed ratio; RUCAM, Roussel Uclaf Causality Assessment Method; ULN,
pper limit of normal.
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0016-5085/08/$34.00
doi:10.1053/j.gastro.2008.09.011
There is a growing awareness that nonprescription


















































ment baseline if baseline level is abnormal) on 2 consec-
























































































December 2008 THE DILIN PROSPECTIVE STUDY 1925ounter dietary supplements, are also important causes
f DILI.9,10 For example, organ toxicity associated with
ormulations that contain ephedra as a major ingredient
as led to their removal by regulatory authorities in some
estern European countries,11,12 and recent reports from
he United States have emphasized the risks of use of
xtracts of Chinese green tea (Camellia sinensis) that con-
ain catechins as a major ingredient.13–15 Because numer-
us dietary supplements are consumed by large numbers
f US adults on a regular basis,16 the hepatotoxicity
f dietary supplements may be significantly underesti-
ated.
It has been hypothesized that host genetic, immuno-
ogic, and environmental factors are important in the
athogenesis of DILI.1–3,5,6,17 Thus, there is a growing
xpectation that use of modern genome-wide association
tudies and other genetic analyses, coupled with careful
henotyping of subjects, will improve the ability to iden-
ify subjects at high or low risk for developing DILI from
arious drugs. This is an important part of the promise
f personalized medicine.18,19
The Drug-Induced Liver Injury Network (DILIN) was
stablished in 2003 as a cooperative agreement among
he National Institutes of Health, 5 academic clinical
enters, and a data coordinating center.20 A major em-
hasis of DILIN has been to establish a protocol for the
dentification and enrollment of patients with clinically
ignificant DILI into a prospective observational study
nd to create a registry and specimen repository of bio-
ogical samples that could be used for mechanistic stud-
es on the etiology and prevention of DILI. The design
nd development of the DILIN prospective study proto-
ol21 and the process of causality assessment22 have been
resented elsewhere. In this report, we describe the im-
licated agents, presenting clinical and laboratory fea-
ures, and short-term outcomes of the first 300 subjects
nrolled in the ongoing DILIN prospective study.
Patients and Methods
The DILIN prospective study is an ongoing mul-
icenter observational study. The study design and pro-
edures were approved by the institutional review board
f each clinical center site, and all enrolled patients pro-
ided written, fully informed consent. The study design
as been described in detail elsewhere.21 In brief, patients
2 years of age or older) were enrolled in this study if
here was a strong clinical suspicion that a liver injury
vent was caused by a medication or an herbal agent
ccurring within 6 months before enrollment. Addition-
lly, patients must meet one of the following biochemical
riteria for enrollment into this study: (1) aspartate ami-
otransferase (AST) or alanine aminotransferase (ALT)
evel 5 times the upper limit of normal (ULN) or alka-
ine phosphatase level 2 times the ULN (or pretreat-g/dL along with elevated AST or ALT or alkaline phos-
hatase level, or (3) international normalized ratio (INR)
1.5 with elevated AST or ALT or alkaline phosphatase
evel. Known or suspected acetaminophen toxicity and a
istory of bone marrow or liver transplantation before
he liver injury event were exclusion criteria. Patients with
nderlying hepatitis C virus (HCV), hepatitis B virus, or
onalcoholic fatty liver disease were eligible if they devel-
ped superimposed DILI; however, those with other
ypes of underlying chronic liver disease (eg, autoimmune
iver disease, sclerosing cholangitis) were ineligible. Sub-
ects with known or suspected acetaminophen hepato-
oxicity or a history of bone marrow or liver transplan-
ation were excluded.
Eligible patients were seen for a baseline study visit,
uring which a medical history and a detailed history of
he liver injury event and exposure to the implicated
gent(s) were obtained and clinical, laboratory, histo-
ogic, and imaging results were extracted from the med-
cal chart. At this time, further laboratory testing was
erformed to more fully characterize the DILI event and
o exclude competing etiologies.1,2 All enrolled individu-
ls were followed up for at least 6 months, and those with
vidence of chronic DILI were asked to return at 12 and
4 months. Chronic DILI was defined as persistent liver-
elated laboratory, radiologic, or histologic abnormalities
t 6 months after DILI recognition.21
In the clinical characterization of DILI, the ratio of
erum ALT (as a multiple of its ULN) to serum alkaline
hosphatase (as a multiple of its ULN) has been desig-
ated as the R (for ratio) value. Hepatocellular DILI is
efined as R  5, cholestatic as R  2, and “mixed” as
 2 to R  5.1,2 For the purpose of this report, “DILI
ecognition” was defined as the time point when patients
et the enrollment criteria. For brevity, herbal remedies,
atural products, vitamins, minerals, and other dietary
upplements are referred to hereafter as “dietary supple-
ents.”
The diagnosis of DILI and the causal relationship
etween the liver injury event and the implicated agent(s)
ere evaluated in a formal and standardized fashion by
he DILIN Causality Committee.22 The causality assess-
ent was conducted for each case by using 2 different
ausality instruments: the widely used Roussel Uclaf Cau-
ality Assessment Method (RUCAM)23–25 and assigning a
ILIN causality score based on the consensus of at least 3
epatologist members of the committee.22 The RUCAM
rovides a semiquantitative evaluation of causality by
ssigning 3 to 3 points to each of its 6 domains.
ased on the final score, a causal relationship between
he implicated agent and the liver injury event was cate-
orized as highly probable (8), probable (6 – 8), possible
3–5), unlikely (1 or 2), or excluded (0).23–25
The DILIN causality score categorizes the strength of
causal association between the implicated agent and the
liver injury event as definite (95% likelihood), highly likely
(75%–95%), probable (50%–74%), possible (25%–49%), and












































alkaline phosphatase, 295  272 U/L; total bilirubin,
















































































1926 CHALASANI ET AL GASTROENTEROLOGY Vol. 135, No. 6pisode was categorized as one of 5 levels (mild, moderate,
oderate-hospitalized, severe, and fatal/transplant) as de-
cribed elsewhere.21
Data Management and Statistical Analyses
Demographic and clinical data for the first 300
atients enrolled into this ongoing study were extracted
n December 1, 2007. Because causality adjudication lags
ehind data collection, causality assessment was com-
leted on only 254 of the 300 cases. No specific sample
ize calculations were made to choose a sample size of
00 patients for this largely descriptive report. Simple
escriptive statistics, that is, mean  SD, median with
5th and 75th percentiles, and frequency distributions,
ere used to characterize the cohort. Between-group dif-
erences were assessed using the Kruskal–Wallis test for
ontinuous variables and the likelihood ratio test for
ategorical variables. For identifying predictors of DILI
everity, the severe and fatal/transplant categories were
ombined into 1 group (severe DILI) and compared with
he other 3 groups combined (mild/moderate DILI) us-
ng the likelihood ratio test. Subsequently, multivariable
ogistic regression analysis, consisting of selected clini-
ally relevant variables (age, sex, race) and those with P 
1 on univariate analysis (alcohol consumption, diabetes,
uration between exposure and DILI recognition, and
attern of liver injury), was conducted to identify factors
ndependently associated with advanced DILI. All statis-
ical analyses were performed using SAS version 8.1 (SAS




The 300 patients included in this report were en-
olled between September 2004 and December 2007. Se-
ected demographic and clinical characteristics are shown in
able 1. Ninety-three percent were adults (18 years), 18%
ere older than 65 years, and 60% were women. Six percent
f patients had known liver disease before the onset of DILI,
nd 3% had underlying human immunodeficiency virus
nfection. Sixty-nine percent had jaundice during the DILI
pisode, and 60% were hospitalized. The median duration
etween first exposure to the implicated agent and DILI
ecognition was 42 (20–117) days. The duration of exposure
efore DILI recognition was not different depending on
ender or race. The median duration between DILI recog-
ition and study enrollment was 49.5 (21–104) days. At the
ime of DILI recognition, the values for serum biochemis-
ries (mean  SD) were as follows: ALT, 788  967 U/L;A single prescription medication was implicated in
17 (73%) of the 300 subjects, whereas single or multiple
ietary supplements were implicated in 28 patients (9%). In
5 patients (18%), more than one prescription medicine or
combination of prescription medicine and dietary supple-
ent(s) was implicated. A complete list of agents implicated
s provided in Supplementary Table 1 (see supplemental
aterial online at www.gastrojournal.org). Among subjects
n whom a single suspect prescription medication was im-
licated, the major classes of agents were as follows: anti-
icrobials (antibacterial agents, antiviral agents, antituber-
ulosis agents, and so on) in 45.5%, central nervous system
gents (antiepileptic agents, antidepressants, antipsychot-
cs) in 15%, immunomodulatory agents in 5.5%, analgesics
nonsteroidal agents, muscle relaxants) in 5%, antineoplastic
gents in 4%, antihypertensive agents in 5%, and lipid-
owering agents in 3.4%. The most common single
mplicated agents were amoxicillin/clavulanate (n 
3), nitrofurantoin (n  13), isoniazid (n  13), and
rimethoprim-sulfamethoxazole (n  13).
Values of R: Types of DILI
The R value was calculated in 298 patients who
ad both serum ALT and alkaline phosphatase values
vailable on the day of DILI recognition. A total of 169
57%) were classified as hepatocellular, 68 (23%) as cho-
estatic, and 61 (20%) as mixed. The clinical and labora-
ory features of patients with the 3 patterns of DILI are
hown in Table 1. Noteworthy were the younger age and
igher proportion of women with hepatocellular injury
n comparison with cholestatic and mixed liver injury.
he absence of preexisting chronic liver disease in the
ixed DILI is noteworthy but of unclear significance.
Causality Assessment
Causality adjudication has been completed in 254
f the 300 patients. Using expert opinion, the likelihood
f DILI as the reason for the liver injury was deemed
efinite in 32%, highly likely in 41%, probable in 14%, and
ossible in 10%. In 9 individuals, DILI was deemed un-
ikely to be responsible for the liver injury event; in these
ases, the final diagnoses were acute hepatitis C in 4,
nknown in 3, and polymyositis and benign recurrent
ntrahepatic cholestasis in 1 each (Supplementary Table 2;
ee supplemental material online at www.gastrojournal.
rg).
The RUCAM scores assigned by the site investigator
ere available for 192 DILI cases caused by a single
rescription agent and were ranked as highly probable in
0%, probable in 45%, possible in 36%, unlikely in 5%, and
xcluded in 4%. Because the RUCAM is designed to at-






































Table 1. Characteristics of Subjects With Different Patterns of Liver Injury





















































December 2008 THE DILIN PROSPECTIVE STUDY 1927han to assess the global likelihood of DILI, cases with
ultiple possible causative agents have more than one
UCAM score and those data are reported elsewhere.22
Course of Liver Injury
Following clinical presentation, the peak serum
iochemistries (mean  SD) were as follows: ALT, 985 
168 U/L; alkaline phosphatase, 390  382 U/L; total
ilirubin, 11.4  10.2 mg/dL; and INR, 1.6  1.4. The
egree of severity of the liver disease was judged to be
ild in 27%, moderate in 19%, moderate-hospitalized in
3%, severe in 15%, and resulting in death or liver trans-
lantation in 6%. Selected demographic and clinical char-
cteristics of patients with severe (severe and fatal/trans-
lant cases combined) and mild/moderate (all other
ases) disease and the results of the univariate analyses
re shown in Table 2. In the multivariate logistic analysis
ncluding age, sex, race, coexistent diabetes mellitus, al-
ohol consumption, smoking, biochemical pattern of
iver injury, and the duration between first exposure and
ILI recognition as covariates, only the presence of dia-
(N  300)
ge, mean  SD (y) 48  18






ody mass index, mean  SD (kg/m2) 26.8  6.5
lcohol use (%) 51
reexisting liver disease (%) 5.7
iabetes mellitus (%) 27
iver biochemistries, DILI recognition (mean  SD)
ALT (U/L) 788  967
Alkaline phosphatase (U/L) 295  272
Total bilirubin (mg/dL) 6.3  6.3
INR 1.5  0.9
iver biochemistries, peak values (mean  SD)
ALT (U/L) 985  116
Alkaline phosphatase (U/L) 390  382
Total bilirubin (mg/dL) 11.4  10.
INR 1.6  1.4
bsolute eosinophils/L (mean  SD) 210  310












OTE. R value could be calculated in 298 patients in whom both ALT
ompare hepatocellular, cholestatic, and mixed categories.etes and alcohol consumption were independently as-
ociated with severe DILI (Supplementary Table 3; see
upplemental material online at www.gastrojournal.org).
he presence of diabetes mellitus was an independent
isk factor for severe DILI (odds ratio, 2.69, 95% confi-
ence interval, 1.14 – 6.45), whereas any alcohol use in the
receding 12 months was a negative predictor of severe
ILI (odds ratio, 0.33; 95% confidence interval, 0.15–
.76). Interestingly, the median duration between first
xposure to the implicated agent and DILI recognition
as significantly longer in severe cases than in mild/
oderate cases (65.5 [33–263] vs 35.5 [19 – 89] days; P 
006), but this association was not statistically significant
n the multivariate analysis (Table 2).
The median duration between DILI recognition and
he peak value for ALT was 1 (0 –7) days, for alkaline
hosphatase was 4 (0 –16) days, and for total bilirubin
as 7 (0 –17) days. There was no statistically significant
elationship between any of these durations and age,
attern of liver injury, implicated agent categories (single
(n  169) (n  68) (n  61) P
44  18 54  16 54  18  .0001
12 26.5 26 .009
65 50 57 .09
76 84 85 .3
11 9 12
4.7 1.5 1
27  7.4 27  5.8 27  4.7 .27
50 50 57 .6
8 7 0 .03
16 25 23 .2
1157  1131 203  160 384  206  .001
190.5  119.5 532  386 305  236  .001
6.2  7.1 7.3  5.6 5.5  4.6 .02
1.6  1.1 1.2  0.3 1.3  0.4 .08
1426  1314 314  451 465  295  .001
248  167 703  542 378  323  .001
10.5  10.1 14  10.8 10.2  9.4 .02
1.9  1.9 1.3  0.5 1.3  0.5 .04
157  153 221  207 389  653 .14
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1928 CHALASANI ET AL GASTROENTEROLOGY Vol. 135, No. 6rescription agent vs dietary supplement[s] vs multiple
gents), and causality or severity scores.
At the 6-month follow-up visit, 13.6% of enrolled pa-
ients had met predefined criteria for chronic DILI, 8%
ad died, and 2.1% had undergone liver transplanta-
ion.21 Features of the implicated agent, patient age, and
attern of DILI were not associated with chronicity, mor-
ality, or need for transplantation (Table 3). Among DILI
ubjects with jaundice at or after presentation (total
erum bilirubin level 2.5 mg/dL), the median duration
etween peak bilirubin level and 50% reduction in total
ilirubin level was 13 days (4 –30 days) and the median






ody mass index, mean  SD (kg/m2)
lcohol use (%)
reexisting liver disease (%)
iabetes (%)
ays between exposure and DILI recognition, median (25th, 75th pe
mplicated agent(s) (%)
Single prescription agent
Single or multiple dietary supplements
Multiple prescription or prescription plus dietary supplements










bsolute eosinophil count/L (mean  SD)













ild DILI: elevated ALT and/or alkaline phosphatase level but serum t
nd/or alkaline phosphatase levels and serum total bilirubin 2
hosphatase, bilirubin, and/or INR levels and patient is hospitalized f
nd/or alkaline phosphatase level and serum bilirubin level 2.5 m
ransplant: patient dies or undergoes transplantation because of DI
hereas nonadvanced DILI consisted of 3 other categories.uration from peak bilirubin level to a level 2.5 mg/dL
as 26.5 days (3–54 days) (Table 4). The patterns and
imes of changes in serum bilirubin levels did not corre-
ate with clinical features of the DILI cases.
Table 5 shows selected characteristics and causes of
eath in the 27 patients with suspected DILI who died or
eceived liver transplantation within 180 days following
he DILI event. Interestingly, among the 18 patients who
ied, the cause of death was judged by the investigators
o be liver related in only 8 (44%). The mortality in
atients with hepatocellular DILI with peak serum total














610  685 1218  1559  .001
309  284 283  247 .60
5.2  5.1 9.1  8.4  .001
1.2  0.3 2.3  1.6  .001
733  726 1513  1734  .001
388  399 401  354 .001
8.9  9.4 18.4  10.2 .50
1.2  0.3 2.9  2.5  .001










0 23  .001
0 2.9 .17
ilirubin level 2.5 mg/dL and INR 1.5; moderate DILI: elevated ALT
g/dL or INR 1.5; moderate-severe DILI: elevated ALT, alkaline
I or if ongoing hospitalization is prolonged; severe DILI: elevated ALT
and hepatic failure (INR 1.5, ascites or encephalopathy); fatal/









































































































December 2008 THE DILIN PROSPECTIVE STUDY 1929n those with hepatocellular DILI with serum total bili-
ubin level 2.5 mg/dL (13.4% vs 2.4%, respectively; P 
04). However, the mortality rate in patients with chole-
tatic DILI with serum total bilirubin level 2.5 mg/dL
as not statistically different than in those with choles-
atic DILI with bilirubin level 2.5 mg/dL (15% vs 10%,
espectively; P  .66). Among 17 patients who died from
iver failure or received a transplant, 14 had hepatocellular
ILI, whereas 2 had mixed and 1 had cholestatic DILI
Table 5).
Dietary Supplements
Dietary supplements were implicated in 33 sub-
ects with DILI; one or more dietary supplements were
mplicated in 28, whereas they were implicated in com-
ination with one or more prescription agents in the
emaining 5. In many cases, multiple agents were being
sed; even when a single preparation was used, it often
ontained multiple herbal or nutritional components, so
hat attribution of liver injury to a single component
as rarely possible. The names of all implicated herbal
gent(s) are shown in Supplementary Table 1 (see sup-
lemental material online at www.gastrojournal.org). The
tated reasons for consuming these dietary supplements
ere muscle building (n  11), weight loss (n  8),
nsomnia (n  2), general well-being (n  2), preventing
ommon cold (n  2), increasing energy levels (n  2),
nd hot flashes (n  1). Compared with 217 cases due to









(n  28) P (n
hronic DILI (%) 13.6 12.7 7.7 .60
-mo mortality (%) 8.0 9.5 0 .20
ransplant (%) 2.1 3.0 0 .50

























26.5 (3, 54) 35 (16, 66) 68 (37, 128) .08ietary supplements showed few differences, none of
hich were statistically significant (Supplementary Table 4;
ee supplemental material online at www.gastrojournal.
rg). Patients with DILI due to dietary supplements had
igher mean levels of serum total bilirubin (14.7  13 vs
0.6  9.9 mg/dL; P  .11) and longer median duration
or the jaundice to resolve (68 vs 35 days; P  .08), but
hese trends were of borderline statistical significance.
here were no instances of Stevens–Johnson syndrome or
eath due to dietary supplements, but one subject with
uspected DILI due to CVS Spectravite developed acute liver
ailure necessitating liver transplantation.
Discussion
This is an initial analysis of an ongoing prospec-
ive study of DILI being performed in the United States,
he primary aim of which is to develop well-characterized
ases of medication-related liver injury on which to con-
uct hypothesis-driven research aimed at developing
eans to diagnose, prevent, and treat DILI. Among the
rst 300 cases identified, more than 100 different medi-
ations, herbal supplements, and dietary supplements
ere implicated. Newly identified hepatotoxic drugs that
ad received Food and Drug Administration warnings
etween 2003 and 2007 were identified by DILIN (eg,
elithromycin, leflunomide, duloxetine), suggesting that
prospective network such as DILIN may be able to
rovide early detection of the hepatotoxic potential of
Age (y) Pattern of DILI
43)
65






(n  61) P
13.3 .96 11.4 17 13.6 .60
13.3 .14 7.5 14.3 2.1 .07
0 .3 0.8 0 0 .70
undice (Serum total bilirubin 2.5 mg/dL) at Recognition










(n  47) P
, 17) 7 (1, 13) .6 7 (3, 14) 7 (1, 17) 6 (0, 20) .8
, 32) 18 (7, 43) .4 14 (7, 32) 15 (4, 31) 22 (9, 31) .4







































































1930 CHALASANI ET AL GASTROENTEROLOGY Vol. 135, No. 6(y)/sex Significant comorbidities Implicated agent(s) pattern score event OutcomeALT (U/L) (U/L) (mg/dL)
1 34/M Human immunodeficiency
virus, hepatitis B virus,
hepatitis D virus
Oxacillin 164 410 1.6 Mixed Possible 106 Death due to drug
overdose
2 70/M Acute myelogenous
leukemia








Oxacillin 366 102 0.9 HC Definite 117 Death due to
cancer




Nitrofurantoin 215 119 0.8 Mixed Very likely 86 Death due to
pulmonary
fibrosis




110 1660 17 CS Possible 133 Death due to
renal failure
6 1/Fa Tetralogy of Fallot Amoxicillin 2108 445 24.6 HC Possible 10 Death: liver failure




Amlodipine 70 339 17.3 HC Very likely 43 Death: liver failure
8 48/M Melanoma, ?HCV Temozolomide 852 151 3.9 HC Not
adjudicated
110 Death due to
cerebral bleed
9 62/F Ulcerative colitis,
hypothyroidism
Cefuroxime Nystatin 1532 435 30.4 HC Not
adjudicated





0 63/M Acute myelogenous
leukemia
XL 999-207 1606 123 5.1 HC Not
adjudicated








Amlodipine 70 339 17.3 CS Possible 43 Death due to
congestive
heart failure
2 66/M Cirrhosis, hyperlipidemia Ezetimibe 
simvastatin
138 145 10.5 Mixed Probable 129 Death: liver failure




Nitrofurantoin 1988 338 31.5 HC Very likely 7 Death: liver failure




Bupropion 1459 292 22.7 HC Probable 104 Death: liver failure






116 1098 10.4 CS Very likely 172 Death: liver failure
6 33/F Multiple sclerosis,
morbid obesity
Interferon beta 1901 224 25.3 HC Definite 87 Death: liver failure






427 175 0.4 HC Possible 144 Death unrelated
to DILI
8 57/M Aplastic anemia Antithymocyte
globulin
417 463 12.8 HC Unlikely 7 Death due to
aplastic anemia
9 44/F None CVS Spectravite
Performance
726 212 25.4 HC Probable 16 Transplant
0 27/M None Diphenoxylate/
atropine
789 210 43 HC Unlikely 147 Transplant




3140 283 33 HC Very likely 31 Transplant
2 41/F None Terbinafine 778 143 29.5 HC Possible 17 Transplant
3 39/F Systemic arterial
hypertension
Isoniazid 850 497 16.0 HC Not
adjudicated
24 Transplant
4 30/F Migraines, gastritis Promethazine 455 861 13.5 Mixed Not
adjudicated
52 Transplant
5 29/F Bipolar disorder,
hyperlipidemia
Valproate Quetiapine 4090 307 18.5 HC Not
adjudicated
7 Transplant
6 59/F Anxiety, depression,
uterine carcinoma































































































































December 2008 THE DILIN PROSPECTIVE STUDY 1931ewly released medications. An important finding was
hat more than one agent was implicated in causing liver
njury in 20% of cases, a frequency significantly higher
han the 9% reported from a similar study that had been
onducted in Spain.26 The reason for this difference is
nclear, but it may reflect higher use of medicines by the
S population. Consistent with previous reports, antimi-
robials represented the single largest class of agents to
ave caused DILI.26 –29 It remains unclear why antimicro-
ials have such a high propensity to cause DILI, but it
ay be related to greater use of antimicrobials in the
eneral population or biological reasons such as under-
ying infection and inflammation conferring increased
usceptibility.30
The proportion of cases with suspected DILI caused by
ietary supplements was nearly 10% and is higher than
eported in the Spanish registry, likely reflecting a greater
se of these products by the US population.26 None of
he subjects with suspected DILI caused by dietary sup-
lements were children. The intake of these compounds
ay be infrequent in children; however, we cannot ex-
lude the possibility that children may be less susceptible
han adults to hepatotoxicity by dietary supplements.
ompounds that claim to promote muscle building and
eight loss were the 2 most common classes of dietary
upplements, accounting for nearly 60% of cases. The
otal number of cases of DILI due to dietary and herbal
upplements was small (n  28), and no single supple-
ent was responsible for more than one case, although,
s a class, supplements that include extracts of green tea
s a major ingredient caused at least 6 of the 28 cases.
The findings regarding the rate of change of serum
otal bilirubin levels after onset of DILI may be of prac-
ical relevance in monitoring and counseling patients
ith DILI (Tables 3 and 4). The total serum bilirubin
evel reached its peak an average of 1 week after DILI
ecognition, and this timing was independent of patient
ge, pattern of liver injury, or whether caused by prescrip-
ion agents or dietary supplements. Among patients with
aundice, it took nearly 1 month on average for the
aundice to resolve, but this interval was longer in the
lderly, in patients with cholestatic forms of DILI, or in
atients with DILI caused by dietary supplements.
Age
(y)/sex Significant comorbidities Implicated agent(s) ALT (U/L)





S, cholestatic; HC, hepatocellular.
Enrolled through exemption.Acute hepatitis C was the final diagnosis in 4 of the 9
ases that were adjudicated as “unlikely” to be DILI.
nti-HCV was initially negative in 2 subjects, but they
ubsequently seroconverted to detectable viremia. In 2
ther patients, initial testing revealed the presence of
nti-HCV, but the site investigators at the time of enroll-
ent believed them to represent chronic rather than
cute hepatitis C, largely because both patients lacked
ecent risk factors for acquiring viral hepatitis. However,
he availability of additional clinical data (eg, liver histol-
gy) made HCV infection rather than DILI the likely
xplanation for the acute event (Supplementary Table 2).
hese 4 patients did not admit to high-risk behaviors (eg,
ecent drug abuse), but 3 had been hospitalized recently.
hese findings suggest that, even in the absence of risk
actors, acute hepatitis C should be excluded by testing
or serum HCV RNA in all patients with suspected DILI,
specially if there is a history of recent hospitalization
nd a hepatocellular pattern of injury. In fact, in light of
hese findings, our protocol was amended to obtain HCV
NA at the baseline visit in all enrolled patients. As
etter diagnostic tests become available for specific
auses of acute liver injury, more cases of suspected
ILI may be found to have other etiologies. Indeed, in
recent series from the United Kingdom, retrospective
esting for antibody to hepatitis E virus in 69 patients
ith presumed DILI identified 6 patients with probably
cute hepatitis E.31
In a cohort study of 461 patients with DILI from
pain, female sex, hepatocellular patterns of liver injury,
nd total serum bilirubin level on presentation were
dentified as independent predictors of acute liver fail-
re.26 In the current US study, there was no relationship
etween female sex and severity of DILI; furthermore, the
ositive association between hepatocellular injury and
everity of DILI was of borderline significance. Total
erum bilirubin levels were higher in patients with severe
ILI, but bilirubin is used in the criteria to define severity
nd therefore was not used in the multivariate analysis of
actors correlating with severity and outcome. In this
tudy, the presence of diabetes mellitus was found to be
n independent risk factor for severe DILI. Diabetes was



















Spain26 and Sweden.29 However, epidemiologic and ani-
mal studies suggest that diabetes is associated with an
increased incidence of acute liver failure and severity of
DILI.32–35 Alcoholism is generally believed to be a risk










































that the average mortality rate in patients with jaundice
and a hepatocellular pattern of injury from DILI is at
least 10%.38
Limitations of our study include the potential for
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ent, points are given in favor of DILI for alcohol intake.
owever, outside of acetaminophen and isoniazid toxicity,
he association between alcohol consumption and suscep-
ibility to DILI has not been evaluated rigorously.1–3 The
nding that alcohol consumption protected against se-
ere DILI in this study was surprising and of uncertain
ignificance. A major difficulty is the variability of defi-
itions of alcohol intake and alcoholism in various stud-
es and causality instruments. In this study, alcohol con-
umption was defined as any alcohol intake in the
receding 12 months. Additional studies are needed to
etermine if alcohol consumption may play a role in
ILI susceptibility by comparing subjects with DILI with
uitably matched controls without DILI. Previous studies
lso have shown associations between severe DILI and
lder age329 and eosinophil counts,35 but these were not
onfirmed in this study. The latter may not have been
dentified due to the lag between DILI recognition and
tudy enrollment (median 42 days). In a study of 95
atients with suspected DILI from Japan,36 the duration
f exposure to the implicated agent was longer in cases of
cute liver failure compared with less severe cases (81 
9 vs 30  44 days, respectively; P  .0001 by univariate
nalysis). In this study, the duration of exposure to the
mplicated agent was significantly longer in individuals
ith severe DILI, but this relationship was not statisti-
ally significant on multivariate analysis.
The mortality rate of DILI is generally high, particu-
arly in cases with jaundice and a hepatocellular pattern
f injury, colloquially known as “Hy’s rule.”37 The 8%
ortality rate in this study is in general agreement with
rior reports.26,29 Although patients with cholestatic
ILI have been thought to have a better prognosis than
hose with hepatocellular DILI,37 this association was not
ound in this study and has not been consistently found
n recent large case series from Europe26,29 (Table 6).
mportantly, most of the fatalities in patients with cho-
estatic forms of DILI were due to reasons other than
iver failure (Table 5). The mortality rate of hepatocellu-
ar forms of liver injury with jaundice in this study was
5%, which is compatible with Hy’s rule, which states
able 6. Mortality Rates and Biochemical Injury Pattern








jörnsson and Olsson29 12.7 7.8 2.4
ndrade et al26 7 5 2
halasani et al (current report) 7.5 14.3 2.1he lack of international standards for diagnosing DILI.
owever, all patients were prospectively studied and had
ndergone a complete serologic, radiologic, and clinical
ssessment by experienced hepatologists. In addition,
ausality was determined by a committee of experts using
tandardized terminology.21 Overall, we may have en-
olled patients with more severe DILI than is encoun-
ered in the general population and in other prior stud-
es.39 This may be due to the fact that hospitalized
atients were more likely to be referred to a DILIN
nvestigator or undergo a complete evaluation. In addi-
ion, nearly 50% of our patients had undergone liver
iopsy. However, a reasonable number of pediatric pa-
ients were enrolled (7%) and a broad distribution of
ace/ethnicities was enrolled. In addition, our limited
ample size precludes robust analysis of risk factors for
ILI outcome. We plan to conduct additional multivar-
ate analyses once the total enrollment increases. Finally,
usceptibility risk factors for DILI will require comparing
nrolled patients with control patients who took the
ame medication but did not develop liver injury. Appro-
riate controls will be recruited as the number of DILI
ases caused by individual medications increases in num-
er.
In summary, DILI in the United States is caused by a
ide variety of prescription and nonprescription medica-
ions, nutritional supplements, and herbal supplements.
he antimicrobials represent the single largest class of
gents that cause DILI, accounting for at least 45% of
ases. At least 20% of patients with DILI ingest more than
ne potentially hepatotoxic agent. Acute hepatitis C
hould be carefully excluded before attributing a case of
cute liver injury to DILI. In this study, coexistent diabe-
es mellitus was an independent risk factor for more
evere DILI, while alcohol consumption was a negative
redictive factor. DILI with jaundice from hepatocellular
iver injury carries a high mortality rate, but the mortality
ate associated with cholestatic forms of DILI is also
ppreciable although often caused by worsening of the
nderlying condition or an unrelated disease. DILI still
epresents an important and problematic cause of acute
iver disease in the United States, and further efforts are
eeded in defining its pathogenesis and developing
eans for its early detection, accurate diagnosis, preven-
ion, and treatment.
Supplementary Data
Note: To access the supplementary material
ccompanying this article, visit the online version of
astroenterology at www.gastrojournal.org, and at doi:
0.1053/j.gastro.2008.09.011.
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Multiple prescription agents or prescription agent(s)
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itrofurantoin (n  13)
soniazid (n  13)
MP/SMX (n  9)
uloxetine (n  6)
alproate (n  6)
nterferon beta (n  6)
iprofloxacin (n  5)
amotrigine (n  5)
ethyldopa (n  5)
elithromycin (5)
henytoin (n  5)
iclofenac (n  4)
erbinafine (n  4)
evofloxacin (n  4)
cases each: atomoxetine, azithromycin, oxacillin,
atorvastatin, etanercept, mercaptopurine,
minocycline, investigational agents
cases each: allopurinol, amiodarone, amoxicillin,
antithymocyte globulin, doxycycline, nevirapine,
ranitidine, celecoxib, desflurane, buproprion,
fluoxetine, fluconazole
case each: acitretin, Avalide, itraconazole,
amitryptiline, lefluonamide, linezolid, amlodipine,
lisinopril, diphenoxylate/atropine, artesunate,
bortezomib, meloxicam, methylphenidate,
moxifloxacin, cefaclor, cephalexin, cefazolin,





docetaxel, efavirez, estradiol, fenofibrate,
fluvastatin, gabapentin, glipizide, Glucovance,
hydralazine, imatinib, interleukin, quinapril,
rifampin, salsalate, sertraline, sevoflurane,
simvastatin, temozolamide, topiramate,
valacyclovir, verapamil, Vytorin, Yasmin
Right approach
Green tea (mega tea, Arizona
green tea)
Lavender oil, Frankincense oil,
Nixia red
Melatonex




Airborne, G3 (Gac fruit juice with
other Chinese fruit juices)
Dexatrim
Creatine
Formula 2 Multivitamin Complex
(Herbalife), Xtra-Cal (Herbalife)




Total Control, Herbalife Xtra-
Cal













Oxodrol 2 (2	 17	 dimethyl 5	
androst 3-one)
N.O. Xplode
Artemisin, Blue Moon cloves,
Kroger-herbal rescue, Blue
moon ginger, Black Walnut,
Hull tincture, Dandelion root,
Cayenne extract, Slippery elm
bean
Warm Wood, Cat’s claw, Chelex
IP6, All one powder, Pectasol,





mega, aloe vera formula,
flaxseed oil, prostate care,
evening primrose oil,





Moxifloxacin, ciprofloxacin  amoxicillin/clavulanate
Pregabalin  simvastatin
Metoprolol, diltiazem  alprazolam






Nitrofurantoin, Source of Life multivitamin mineral 
full-spectrum mineral







Amoxicillin, Methyl 1-D  Cell-Tech
Allopurinol  rosiglitazone
Leflunomide  lovastatin
























Lamotrigine, lovastatin  lithium
Glibenclamide  doxyclycine
Azithromycin  TMP/SMX
Diclofenac, lovastatin  clindamycin
Valsartan  levofloxacin
Valacyclovir  Advicor
NOTE. This includes all cases regardless of their level of causality association. It is difficult to describe causality scores in this table; for example,
23 cases of amoxicillin/clavulanate will have different levels of causality scores. See Supplementary Table 2 to see compounds implicated in
“unlikely” DILI cases (n  9).
TMP/SMX, trimethoprim-sulfamethoxazole.























69 Female Hepatocellular 0.6 Atorvastatin Polymyositis Additional data became available during the follow-up period
that suggested an alternate diagnosis.
39 Female Hepatocellular 13.9 Linezolid Acute
hepatitis C
Hepatitis C antibody was negative initially, but both anti-HCV
antibody and hepatitis C RNA were positive subsequently
and repeatedly. Two years following this episode, she
spontaneously cleared her hepatitis C. Patient had a
history of recent hospitalization for the treatment of
cellulitis and osteomyelitis.





Initially his liver biochemistries improved upon
discontinuation of suspected agents. However, he
experienced recurrent episodes of jaundice with
spontaneous improvement and exacerbation. He
eventually died of liver failure at a local hospital.
16 Female Cholestatic 23 TMP/SMX Recurrent
cholestasis
Additional history revealed that this patient had recurrent
benign intrahepatic cholestasis with spontaneous
exacerbations and had received TMP/SMX on multiple
previous occasions.






There was strong suspicion that this individual has
consumed but not admitted use of anabolic steroids.
Temporal relationship made Lomotil an unlikely culprit.
56 Female Mixed 27 Gentamycin Acute
hepatitis C
Patient’s anti-HCV antibody and HCV polymerase chain
reaction were positive during the acute episode, but the
site investigator considered it to be preexisting chronic
infection and acute jaundice was believed to be unrelated
to HCV. The Causality Committee adjudicated the acute
event as unlikely due to DILI and assigned acute
hepatitis C as the more likely diagnosis. Patient had
recent hospitalization during which he received
gentamicin.




Anti-HCV antibody tested during the acute event by the
referring physician was negative, forming one of the
bases for his enrollment, but his enrollment laboratory
tests revealed positive anti-HCV antibody and HCV
polymerase chain reaction. Patient had recent
hospitalization and surgery.
51 Male Hepatocellular 17.1 Levofloxacin Acute
hepatitis C
Anti-HCV antibody testing at enrollment was positive, but
the site investigator considered the jaundice episode to
be unrelated to hepatitis C because the patient lacked
recent risk factors and also the episode had a strong
temporal relation to levofloxacin exposure. However, the
Causality Committee adjudicated the jaundice episode as
unlikely related to DILI and considered acute hepatitis C
as the more likely possibility.
57 Female Cholestatic 12.8 Antithymocyte
globulin
Unknown Temporal and exposure to multiple agents and other acute
illnesses made DILI an unlikely possibility.
MP/SMX, trimethoprim-sulfamethoxazole.Supplementary Table 3. Variables Independently








Variable DF Wald 
2 Pr  
2
ge 1 1.6235 0.2026
ex 1 0.0011 0.9741
ace 4 1.9542 0.7442
lcohol 1 6.8321 0.0090




attern of liver injury 2 4.0097 0.1347
Supplementary Table 4. Characteristics of Patients With Suspected DILI Caused by Dietary Supplements as Compared With
Single Prescription Agents
Single prescription agent group
(n  217)
Dietary supplement(s) group
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emale (%) 61 50 .30
ody mass index (kg/m2), mean  SD 26.8  6.7 26.7  5.2 .70
elf-reported race (%)
White 78 82 .70
Black 10 7
Asian 5 0
reexisting liver disease (%) 5 10 .30
rior drug allergies (%) 49 46 .80
iabetes (%) 27 21 .65
lcohol (%) 49 68 .05
urrent smoking (%) 17 11 .56
ays between (median, 25th and 75th
percentiles)
Exposure and DILI recognition 40 (19, 117) 54 (36, 109) .20
DILI recognition and peak bilirubin level 7 (1, 17) 6.5 (4, 13) .97
Peak bilirubin level and 50% reduction 17 (8, 33) 19 (11, 58) .36
Peak bilirubin level and level 2.5 mg/dL 35 (16, 66) 68 (37, 128) .08
tevens–Johnson syndrome (%) 1.4 0 1.00
bsolute eosinophil count/L (mean  SD) 191  341 128  105 .30
iver biochemistries, peak values
ALT (U/L), mean  SD 996  1217 1028  1016 .80
Alkaline phosphatase (U/L), mean  SD 360  305 300  284 .26
Total bilirubin (mg/dL), mean  SD 10.6  9.9 14.7  13.0 .11
INR 1.6  1.5 1.6  2.2 .15
iochemical pattern (%)
Hepatocellular 56 63 .80
Cholestatic 24 17
Mixed 20 21
everity of liver injury (%)






Definite 34 39 .90




hronic DILI (%) 12 9 1.00
eath (%) 11 0 .14
iver transplant (%) 0.6 3.5 1.00
